All Clinical Trials

A listing of 23116 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Offer

Lose 20% of Body Weight With GLP-1's

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).

Get $50 off your first order using promo code: policy-lab-50

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Buy Retatrutide Online Through Celia

Recruiting

Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.

Conditions:

Healthy

Learn More

Featured Trial

COVID-19 Vaccine Clinical Trial (Compensation Provided)

Recruiting

Healthy adults ages 50-64 may qualify. You may be eligible if you haven’t received a COVID-19 vaccine and haven’t had COVID-19 in the last 90 days.

Qualified participants may receive compensation for time and travel.

Conditions:

Healthy

Vaccine

COVID19

COVID-19

COVID-19 Vaccine

Learn More

Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

NCT06968195

Recruiting

This phase I trial studies the side effects and best dose of RPCAR01 chimeric antigen receptor (CAR) T cells and to see how well it works in treating patients with GPC3 expressing hepatocellular carcinoma (HCC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). In GPC3 expressing HCC cancerous cell tissue overexpresses, or ma... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Roswell Park Cancer Institute, Buffalo, New York

Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8

Learn More ›

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

NCT06562543

Recruiting

High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib f... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Central Alabama Research, Birmingham, Alabama +44 locations

Central Alabama Research, Birmingham, Alabama

University of Alabama at Birmingham, Birmingham, Alabama

Ironwood Cancer and Research Centers, Chandler, Arizona

University of Arizona, Tucson, Arizona

University of California San Diego, La Jolla, California

University of Southern California, Los Angeles, California

PIH Health Whittier Hospital, Whittier, California

Christiana Care Health Services, Newark, Delaware

University of Florida, Gainesville, Florida

University of Miami, Miami, Florida

Baptist Health - Miami Cancer Institute, Miami, Florida

Emory University, Atlanta, Georgia

Hope and Healing Cancer Services, Hinsdale, Illinois

Indiana University, Indianapolis, Indiana

Our Lady of the Lake Physician Group - LSU Health Baton Rouge Oncology, Baton Rouge, Louisiana

Willis Knighton Cancer Center, Shreveport, Louisiana

Mercy Medical Center, Baltimore, Maryland

Boston Medical Center, Boston, Massachusetts

Hattiesburg Clinic, Hattiesburg, Mississippi

Saint Luke's Cancer Institute, Kansas City, Missouri

Midwest Oncology Associates - Kansas City, Kansas City, Missouri

SSM Health St. Louis DePaul Hospital, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Capital Health Medical Center - Hopewell, Pennington, New Jersey

Albert Einstein College of Medicine, Bronx, New York

James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York

Columbia University, New York, New York

Zangmeister Cancer Center, Columbus, Ohio

Hightower Clinical Research, Oklahoma City, Oklahoma

Jefferson Health, Philadelphia, Pennsylvania

Fox Chase Cancer Center | Philadelphia, PA, Philadelphia, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

University of Tennessee -- Memphis, Memphis, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

University of Texas Southwestern Medical Center, Dallas, Texas

Renovatio Clinical, El Paso, Texas

Oncology Consultants - Memorial City Location, Houston, Texas

Baylor College of Medicine, Houston, Texas

BRCR Global, Katy, Texas

Renovatio Clinical, The Woodlands, Texas

Tranquil Research, Webster, Texas

UC Irvine Medical Center - Chao Family Comprehensive Cancer, Orange, Virginia

Virginia Commonwealth University, Richmond, Virginia

Medstar Speciality Hospital, Northwest, Washington

Fundacion de Investigacion de Diego (FDI Clinical Research), San Juan, Not set

Conditions: Colorectal Cancer

Learn More ›

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06961370

Recruiting

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in GA secondary to AMD after multiple unilateral intravitreal (IVT) doses.

Gender:

ALL

Ages:

55 years and above

Trial Updated:

08/14/2025

Locations: Associated Retina Consultants - Phoenix - DocTrials - PPDS, Phoenix, Arizona +15 locations

Conditions: Geographic Atrophy, Age-related Macular Degeneration

Learn More ›

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

NCT06533748

Recruiting

This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma. Primary Objective * To assess if the flow-cytometry assessed MRD-negative remission rate following an immunotherapy-based Induction in NCI-high risk patients without favorable genetic features is higher than the results of similar patients trea... Read More

Gender:

ALL

Ages:

Between 1 year and 18 years

Trial Updated:

08/14/2025

Locations: St. Jude Children's Research Hospital, Memphis, Tennessee

Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

Learn More ›

Acute Effects of THC in Older Adult

NCT06948136

Recruiting

The primary objective of this study is to determine if increasing age confers greater vulnerability to the acute A) cognitive (e.g., memory, attention, psychomotor function), B) subjective (e.g., anxiogenic and rewarding effects), and C) cardiovascular (heart rate and blood pressure), effects of THC in adults \> 21 years old. The secondary aims of the study are to explore age-related acute effects of THC on electrophysiological indices of information processing (e.g., auditory steady-state respo... Read More

Gender:

ALL

Ages:

21 years and above

Trial Updated:

08/14/2025

Locations: VA Connecticut Healthcare System, West Haven, Connecticut

Conditions: Age-related Cognitive Decline

Learn More ›

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273

Recruiting

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

08/14/2025

Locations: Local Institution - 0120, Glendale, Arizona +124 locations

Local Institution - 0120, Glendale, Arizona

Local Institution - 0022, Bentonville, Arkansas

Local Institution - 0021, Little Rock, Arkansas

Local Institution - 0038, Little Rock, Arkansas

Local Institution - 0057, Rogers, Arkansas

Local Institution - 0027, Anaheim, California

Local Institution - 0050, Bellflower, California

Local Institution - 0044, Cerritos, California

Local Institution - 0037, Culver City, California

Local Institution - 0085, Garden Grove, California

Local Institution - 0056, Montclair, California

Local Institution - 0039, Orange, California

Local Institution - 0043, Riverside, California

Local Institution - 0123, Torrance, California

Local Institution - 0131, New Haven, Connecticut

Local Institution - 0026, Hialeah Gardens, Florida

Local Institution - 0059, Hollywood, Florida

Local Institution - 0053, Hollywood, Florida

Local Institution - 0047, Miami Lakes, Florida

Local Institution - 0025, Miami Springs, Florida

Local Institution - 0030, Miami, Florida

Local Institution - 0028, Miami, Florida

Local Institution - 0045, Saint Petersburg, Florida

Health Synergy Clinical Research, Stuart, Florida

Local Institution - 0052, Atlanta, Georgia

Local Institution - 0054, Atlanta, Georgia

Local Institution - 0023, Decatur, Georgia

Local Institution - 0024, Savannah, Georgia

Local Institution - 0031, Chicago, Illinois

Local Institution - 0020, Chicago, Illinois

Local Institution - 0049, Gaithersburg, Maryland

Local Institution - 0029, Flowood, Mississippi

Local Institution - 0042, Saint Louis, Missouri

Local Institution - 0121, North Las Vegas, Nevada

Local Institution - 0122, North Las Vegas, Nevada

Local Institution - 0058, Marlton, New Jersey

Local Institution - 0130, Marlton, New Jersey

Local Institution - 0033, Staten Island, New York

Local Institution - 0124, Charlotte, North Carolina

Local Institution - 0055, Cincinnati, Ohio

Local Institution - 0040, North Canton, Ohio

Local Institution - 0048, DeSoto, Texas

Local Institution - 0046, Houston, Texas

Local Institution - 0036, Irving, Texas

Pillar Clinical Research - Richardson, Richardson, Texas

Local Institution - 0128, ABB, Ciudad Autónoma De Buenos Aires

Local Institution - 0127, Córdoba, Not set

Local Institution - 0126, Mendoza, Not set

Local Institution - 0105, St Leonards, New South Wales

Local Institution - 0087, Brisbane, Queensland

Local Institution - 0082, Burgas, Not set

Local Institution - 0107, Novi Iskar, Not set

Local Institution - 0081, Pleven, Not set

Local Institution - 0113, Sliven, Not set

Local Institution - 0114, Vratsa, Not set

Local Institution - 0018, Zagreb, Grad Zagreb

Local Institution - 0017, Zagreb, Not set

Local Institution - 0019, Zagreb, Not set

Local Institution - 0103, Zagreb, Not set

Local Institution - 0129, Zagreb, Not set

Local Institution - 0109, Győr, Győr-Moson-Sopron

Local Institution - 0110, Budapest, Not set

Local Institution - 0108, Budapest, Not set

Local Institution - 0111, Vadodara, Gujarat

Local Institution - 0079, Kozhikode, Kerala

Local Institution - 0077, Ludhiana, Punjab

Local Institution - 0078, Hyderabad, Telangana

Local Institution - 0080, Hyderabad, Telangana

Local Institution - 0076, Kolkata, West Bengal

Local Institution - 0068, Hod HaSharon, HaMerkaz

Local Institution - 0075, Ness Ziona, HaMerkaz

Local Institution - 0084, Petah Tikva, HaMerkaz

Local Institution - 0067, Ramat Gan, HaMerkaz

Local Institution - 0106, Be'er Sheva, Southern

Local Institution - 0074, Jerusalem, Not set

Local Institution - 0066, Milano, Lombardia

Local Institution - 0083, Pisa, Toscana

Local Institution - 0065, Siena, Toscana

Local Institution - 0070, Ancona, Not set

Local Institution - 0069, Genova, Not set

Local Institution - 0008, Konan, Aichi

Local Institution - 0003, Toyoake, Aichi

Local Institution - 0001, Ichikawa, Chiba

Local Institution - 0063, Kitakyushu, Fukuoka

Local Institution - 0015, Obihiro, Hokkaido

Local Institution - 0005, Sapporo, Hokkaido

Local Institution - 0007, Sakai-shi, Osaka

Local Institution - 0011, Karatsu-shi, Saga-Ken

Local Institution - 0016, Iruma, Saitama

Saitama Konan Hospital, Kumagaya, Saitama

Local Institution - 0009, Itabashi City, Tokyo

Local Institution - 0072, Kodaira, Tokyo

Kuramitsu Hospital, Fukuoka, Not set

Local Institution - 0004, Miyazaki, Not set

Local Institution - 0010, Osaka, Not set

Local Institution - 0013, Osaka, Not set

Showa Medical University Karasuyama Hospital, Tokyo, Not set

Local Institution - 0002, Wakayama, Not set

Local Institution - 0014, Yamagata, Not set

Local Institution - 0086, Auckland, Not set

Local Institution - 0092, Warsaw, Mazowieckie

Local Institution - 0090, Bialystok, Podlaskie

Local Institution - 0093, Gdańsk, Pomorskie

Local Institution - 0088, Poznań, Wielkopolskie

Local Institution - 0091, Tuszyn, Łódzkie

Local Institution - 0089, Rybnik, Śląskie

Local Institution - 0095, Bucharest, București

Local Institution - 0096, Bucharest, București

Local Institution - 0098, Bucharest, București

Local Institution - 0099, Bucharest, București

Local Institution - 0101, Bucharest, București

Local Institution - 0102, Bucharest, București

Local Institution - 0104, Bucharest, București

Local Institution - 0094, București, Not set

Local Institution - 0097, Iași, Not set

Local Institution - 0100, Sanpetru /Brasov, Not set

Local Institution - 0118, Kosice, Košický Kraj

Local Institution - 0119, Košice, Košický Kraj

Local Institution - 0117, Vranov nad Topľou, Prešovský Kraj

Local Institution - 0115, Barcelona, Barcelona [Barcelona]

Local Institution - 0071, Barcelona, Catalunya [Cataluña]

Local Institution - 0064, Bilbo, País Vasco

Local Institution - 0125, Nacka, Stockholms Län [se-01]

Local Institution - 0112, Uppsala, Uppsala Län [se-03]

Local Institution - 0116, Gothenburg, Västra Götalands Län [se-14]

Conditions: Bipolar Disorder Type I With Mania

Learn More ›

PanTheR Registry Trial

NCT06805461

Recruiting

This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to solid tumors using the RenovoCath® catheter.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Baptist Health South Florida, Coral Gables, Florida +2 locations

Conditions: Solid Tumors

Learn More ›

FiberLocker® System Augmentation of Rotator Cuff Repairs

NCT06918041

Recruiting

The purpose of this study is to prospectively evaluate healing, functional clinical outcomes, and safety of arthroscopic rotator cuff repairs augmented with the FiberLocker® System (encompassing the SpeedPatch® PET and the FiberLocker® Instrument SN). The primary outcome measure is healing evaluation based on Magnetic Resonance Imaging (MRI) at a minimum of 6 months post-operatively. The secondary outcome measures are the Sugaya classification, Goutallier Stage and tendon quality based on MRI... Read More

Gender:

ALL

Ages:

Between 30 years and 70 years

Trial Updated:

08/14/2025

Locations: MedStar Health Research Institute, Columbia, Maryland +1 locations

Conditions: Rotator Cuff Tear, Rotator Cuff Tears, Rotator Cuff Tears of the Shoulder

Learn More ›

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734

Recruiting

The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies. This study is seeking participants who: * have advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, or pancreatic ductal adenocarcinoma (PDAC); * are able to provide tumor tissue samples; * have measurable disease. All participants will receive while at the... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Presbyterian/ St. Lukes Medical Center, Denver, Colorado +8 locations

Conditions: Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Learn More ›

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

NCT06637514

Recruiting

The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 4 in 5 (or 80%) chance of receiving JNT-517. The study will last for up to 63 days including a Screening period, Treatment period and Follow-up period for safety. Participants will: * Tak... Read More

Gender:

ALL

Ages:

Between 12 years and 17 years

Trial Updated:

08/14/2025

Locations: University of Texas Southwestern Medical Center, Dallas, Texas

Conditions: Phenylketonuria (PKU)

Learn More ›

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

NCT06898957

Recruiting

The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

08/14/2025

Locations: Yale New Haven Hospital, New Haven, Connecticut +9 locations

Conditions: Small Cell Lung Cancer

Learn More ›

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

NCT06995820

Recruiting

The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD1613 in healthy participants, including Japanese and Chinese descent.

Gender:

ALL

Ages:

Between 18 years and 50 years

Trial Updated:

08/14/2025

Locations: Research Site, Glendale, California

Conditions: Healthy

Learn More ›